Jagsonpal Pharmaceuticals LimitedQ1 FY27 Results & Financial Update
Jagsonpal Pharmaceuticals Limited: Q1 FY27 standalone results and company financials – revenue ₹82.23 Cr, PAT ₹13.19 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Jagsonpal Pharmaceuticals price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Jagsonpal Pharmaceuticals Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Jagsonpal Pharmaceuticals delivered a positive operating performance for the first quarter of fiscal 2027, reporting a standalone revenue from operations of ₹82.23 crore (₹822 million), reflecting an 8.8% year-on-year increase compared to ₹75.6 crore in Q1 FY26 s.
According to company performance disclosures, operating EBITDA (calculated pre-ESOP) expanded by 21.4% year-on-year to ₹19.1 crore, while operating EBITDA margin rose by 241 basis points to 23.2%, driven by operating leverage and higher medical representative productivity.
Net profit after tax for the quarter reached ₹13.19 crore (₹132 million), marking a 22.2% growth compared to ₹10.8 crore in the corresponding period of the previous fiscal year, with PAT margin expanding to 16.0%.
The company outperformed the broader Indian Pharmaceutical Market (IPM), with Pharmarack data cited by management indicating a 18.9% growth rate for Jagsonpal versus 11.6% for the IPM, leading to a four-rank improvement to #88 in the market.
During the quarter, Jagsonpal completed the acquisition of an 85% controlling stake in Aequitas Healthcare for an all-cash consideration of ₹20.8 crore, establishing an immediate footprint in the hospital supplies segment.
Capital allocation initiatives during the period included the conclusion of a ₹40 crore share buyback, which resulted in a 340-basis-point improvement in return on capital employed.
Despite significant cash outflows for the Aequitas acquisition and the share buyback program, the company preserved a robust liquidity profile, ending the quarter with cash and cash equivalents of ₹170 crore.
01 · Business model
What does Jagsonpal Pharmaceuticals do?
Jagsonpal Pharmaceuticals Limited is an India-centric pharmaceutical company with a operating history spanning over four decades, specializing in branded generics, trade generics, and over-the-counter products.
The company maintains a strong therapeutic presence focused primarily on Gynaecology, Orthopaedics, Dermatology, and Child-care segments, supported by a pan-India distribution network across more than 4,000 towns and cities.
Jagsonpal operates an asset-light business model, utilizing outsourced research and development partnerships alongside contract manufacturing relationships with leading Indian contract manufacturing organizations.
Commercial operations are driven by an experienced internal field force of approximately 1,000 professional sales representatives interacting with over 50,000 doctors nationwide.
02 · Historical context
What shaped the business before this quarter
Over the same FY22–FY26 period, operational PAT increased by 2.4x to reach ₹44.6 crore, while cumulative free cash conversion improved significantly to 92% of EBITDA.
The company systematically reduced its net working capital requirements from 59 days of sales in FY22 down to 11 days by FY26.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹82.23 Cr |
| Total income | ₹85.07 Cr |
| Profit before tax | ₹17.68 Cr |
| Profit after tax | ₹13.19 Cr |
| EPS | ₹1.98 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue growth was underpinned by enhanced productivity from the ~1,000-strong medical representative team and sustained demand across core power brands.
Jagsonpal outpaced the broader Indian Pharmaceutical Market, registering 18.9% growth versus the IPM's 11.6% according to Pharmarack tracking.
Top 10 brands accounted for approximately 58% of revenue, with key labels such as Maintane Injection demonstrating strong 43% year-on-year growth.
What drove margins
Operating EBITDA margin expanded by 241 basis points year-on-year to 23.2%, benefiting from operating leverage as fixed overheads were distributed over a larger revenue base.
Gross profit increased 10.1% year-on-year to ₹53.6 crore, with gross margin improving to 65.2% from 64.4% in Q1 FY26.
05 · Demand, customers & order book
Where demand is coming from
Field teams maintained active professional engagement with over 35,000 gynaecologists, 10,000 orthopedists, and 9,700 pediatricians across India.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company maintained strong standing in Corporate CVM rankings, including #2 in Orthopedics, #7 in Gynecology, #17 in Pediatrics, and #30 in Dermatology.
Geography and market mix
Distribution operations covered over 4,000 towns and cities via 1,200 distributors and 18 stocking points nationwide.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Manufacturing operations remained fully outsourced to leading Indian contract manufacturing organizations complying with WHO-GMP and ISO 9001:2015 standards with over 300 quality checks.
Projects, capex and execution
Capital expenditure focused on the completion of the 85% acquisition of Aequitas Healthcare funded via internal accruals.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Acquired an 85% stake in Aequitas Healthcare for ₹20.8 crore in all-cash consideration, gaining access to a ₹53.3 crore revenue base and a network across 1,000+ hospitals and 4,000+ doctors.
Launched Ventrixa (Aztreonam + Avibactam combination) targeting the broader ₹1,452 crore Meropenem market which grew 12.9% year-on-year.
09 · Reported developments
What changed operationally
Delivered 8.8% revenue growth and 22.2% PAT growth alongside a 340-basis-point ROCE improvement resulting from disciplined capital return actions.
10 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Net working capital stood at ₹12.0 crore as of June 30, 2026, compared to ₹11.0 crore as of March 31, 2026, and ₹9.9 crore as of June 30, 2025.
Capital allocation & funding
The company maintained a debt-light, cash-rich balance sheet with cash and cash equivalents of ₹170 crore following the Aequitas acquisition and the ₹40 crore share buyback.
11 · Management guidance & targets
What management is targeting from here
Management targeted scaling Aequitas Healthcare to generate over ₹10 crore in EBITDA by Year 2 post-integration, with higher contribution expected from H2 FY27 and FY28 onwards.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
Share Buyback Completion
Concluded a ₹40 crore share buyback program during the quarter, reducing shareholder funds to ₹2,548 million while maintaining robust financial health.
13 · Previous-quarter changes
What changed since the previous quarter
Revenue expanded 28.1% sequentially from ₹64.2 crore in Q4 FY26 to ₹82.2 crore in Q1 FY27, while operating EBITDA rose 80.7% over the same period.
14 · Key Q&A
The quarter, answered directly
What does Jagsonpal Pharmaceuticals do?
Jagsonpal Pharmaceuticals Limited is an India-centric pharmaceutical company with a operating history spanning over four decades, specializing in branded generics, trade generics, and over-the-counter products.
What is the clearest takeaway from Q1 FY27?
Jagsonpal Pharmaceuticals delivered a positive operating performance for the first quarter of fiscal 2027, reporting a standalone revenue from operations of ₹82.23 crore (₹822 million), reflecting an 8.8% year-on-year increase compared to ₹75.6 crore in Q1 FY26 s.
What drove revenue or demand?
Revenue growth was underpinned by enhanced productivity from the ~1,000-strong medical representative team and sustained demand across core power brands.
What mattered most for margins or profitability?
Operating EBITDA margin expanded by 241 basis points year-on-year to 23.2%, benefiting from operating leverage as fixed overheads were distributed over a larger revenue base.
What changed operationally beyond the headline numbers?
Manufacturing operations remained fully outsourced to leading Indian contract manufacturing organizations complying with WHO-GMP and ISO 9001:2015 standards with over 300 quality checks.
What is management guiding or targeting from here?
Management targeted scaling Aequitas Healthcare to generate over ₹10 crore in EBITDA by Year 2 post-integration, with higher contribution expected from H2 FY27 and FY28 onwards.
15 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
16 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Aequitas Integration Progress: Monitor cross-selling execution of Jagsonpal portfolios across Aequitas's network of 1,000+ hospitals and subsequent contribution to H2 FY27 earnings.
- 02
New Product Ramp-up: Track uptake and market penetration of newly launched specialty offerings such as Ventrixa in institutional and retail channels.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.